The global unstable angina therapeutics market is expected to witness a favorable growth during the forecast period.
Albany, NY -- (SBWIRE) -- 05/09/2018 -- Angina is a condition characterized by the pain in chest, neck, shoulders or arms mainly caused due to blockages in heart arteries due to which heart is deprived of oxygen. There are two major types of angina namely unstable and chronic stable angina. Chronic stable angina also known as angina pectoris is a common form of chest pain caused due to lack of oxygen supply to the heart. It usually occurs during rigorous exercise and pain is alleviated when the person rests for some time. Whereas, unstable angina is a chest pain that occurs suddenly and becomes worse with time. This type of chest pain occurs without cause and can lead to heart attack. Patients with unstable angina needs emergency treatment involving hospitalization and medications that helps in stabilizing the condition. Atherosclerosis (plaque deposition in the arterial walls) is the principal cause of unstable angina. Diagnosis of unstable angina is facilitated by blood tests, echocardiogram (ECG), coronary angiography and echocardiography.
Request Report for Table of Contents @ https://www.persistencemarketresearch.com/toc/5837
Treatment options depends on the severity of the condition; primary medication options include the use of blood thinners such as heparin or clopidogrel. Also, medications are administered to reduce the angina symptoms such as blood pressure, arrhythmias, cholesterol, anxiety and others. If there is a blockage or narrowing of artery, then the physician may recommend invasive procedures such as angioplasty and in severe cases, heart bypass surgery is recommended. Unstable angina therapeutics market exhibit immense growth potential majorly due to increasing number of patients with cardiac disorders, increasing use of tobacco, improper food habits and changing lifestyles.
Unstable angina therapeutics market can be analyzed on the basis of several products used in treatment of the same. Some of the products used in the treatment are calcium channel blockers, low molecular weight heparins, nitrates, statins, angiotensin-converting enzyme inhibitor, beta blockers and others. Also, a pipeline analysis of unstable angina therapeutics can be elucidated. The major factors influencing the growth of the market are rise in number of patients undergoing treatment for unstable angina and approval of novel therapies that render high safety and efficacy.
Rivaroxaban, varespladib and otamixaban are few examples of novel therapeutics that are currently in the late stage of clinical development. These products if approved are expected to be marketed at premium prices. However, low penetration of novel therapies in generics-dominated market would decelerate the growth of unstable angina therapeutics market. Other factors such as patent expirations and high cost of drug development also might hamper the growth of the market.
Request to View Sample of Research Report @ https://www.persistencemarketresearch.com/samples/5837
Bayer Healthcare, Sanofi, Anthera Pharmaceuticals and Ablynx are some of the companies operating in this market.